Begins Coverage on Galectin Therapeutics (NASDAQ:GALT) started coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a research note issued to investors on Monday morning. The firm issued a hold rating on the stock. Separately, HC Wainwright restated a buy rating and set a $11.00 target price on shares of Galectin Therapeutics in a report on Tuesday, August […]

Leave a Reply

Your email address will not be published.

Previous post Russian oil trading well above price cap
Next post Initiates Coverage on Can-Fite BioPharma (NYSE:CANF)